











# SEDE

Auditorium San Gaetano - Via Altinate, 71 - Padova

### MODALITÀ D'ISCRIZIONE

Il corso è gratuito con iscrizione obbligatoria al sito **www.sabiwork.it** Riservato a 200 partecipanti per le seguenti figure professionali:

- Medico Chirurgo, tutte le discipline
- Infermiere
- Tecnico sanitario di laboratorio biomedico
- Biologo

# **CREDITI ECM**

N. 11,9

# **RESPONSABILE SCIENTIFICO**

Prof. Paolo Angeli Prof. Roberto Vettor

# PROVIDER ECM (ID. 773) E SEGRETERIA ORGANIZZATIVA

SABI WORK - Via Ospedale Civile, 33 - 35121 Padova Tel. 049 7387069 - segreteria@sabiwork.it www.sabiwork.it



# SEPTEMBER 2024 20<sup>th</sup>-21<sup>st</sup> - PADUA -



Con il contributo incondizionato di







MADRIGAL





echosens

THE NEW KEYWORDS IN THE MANAGEMENT OF METABOLIC DYSFUNCTION ASSOCIATED LIVER DISEASE (MASLD): INNOVATION, PREVENTION AND MULTIDISCIPLINARITY



# FIRST DAY: 20th SEPTEMBER 2024

9.00 am	Welcome and Introduction Paolo Angeli; Roberto Vettor				
INNOVATION					
9.15 am	First Session: Pathophysiology of MASLD (First Part) Chairs: Pietro Maffei; Mario Luca Morieri				
9.15 am	<b>Human Adipose Tissue and Liver</b> Saverio Cinti, Italy				
9.35 am	Metabolic Flux in Adipose Tissues and Liver in Health and Disease Amalia Gastaldelli, Italy				
9.55 am	<b>The Role of Primary Cilium in Adipogenesis and Fibrosis</b> Silvia Bettini; Gabriella Milan, Italy				
10.15 am	Adipose Tissue and Whole Body Metabolism in MASLD: Insights from Twin Studies Kirsi Pietiläinen, Finland				
10.35 am	Discussion: Federico Capone; Angelo Di Vincenzo				
10.55 am	Coffee break				
11.25 am	<b>State of the Art Lecture</b> Chairs: Agatella Barchitta; Maurizio Cesari				
	<b>Pathophysiological Relationship between Liver and Heart</b> <i>Gabriele G. Schiattarella, Italy</i>				
11.55 am	Second Session: Pathophysiology of MASLD (Second Part) Chairs: Marco Di Pascoli; Marco Rossato				
11.55 am	Adipose Tissue-Liver-Immune System Cross Talk and the Development of Metabolic Dysfunction Associated Liver Disease (MASLD) Roberto Vettor, Italy				
12.15 pm	<b>The Metabolic Benefits of CD300e: Unlocking the Immune</b> <b>Receptor's Role in Combating Obesity-relating Disorders</b> <i>Marina De Bernard, Italy</i>				
12.35 pm	Mitochondrial Bioenergetics Calcium Handling in Adipose Tissue and Liver Rosario Rizzuto, Italy				

12.55 pm	Genetic and Acquired Causes of MASLD: Lessons from in Vivo Studies in Humans Hannele Yki-Järvinen, Finland	SECOND DAY: 21 <sup>st</sup> SEPTEMBER 2024		12.10 pm	The Metabolic MicroRNA miR-22 as a Therapeutic Target for the Treatment of Obesity and MASLD/MASH Riccardo Panella, Denmark	
1.15 pm	Discussion: Giuseppe Maiolino; Chiara Piovella			12.30 pm	Pharmacological Innovation in Metabolic Diseases Elcin Darendeli, Denmark	
1.35 pm <b>PREVENTION</b>			MULTIDISCIPLINARITY		Innovation in Obesity Therapy and its Complications Eva Lau, Portugal	
2.30 pm	Opening Ceremony	8.30 am	Fifth Session Round Table: From Screening to Link of Care	1.30 pm	Discussion: Francesca Dassie, Roberto Fabris	
3.00 pm	State of the Art Lecture		Chairs: Massimo Annicchiarico, Giuseppe Dal Ben, Michele Tessarin	1.50 pm	Lunch	
	Chair: Paolo Angeli; Lorenza Di Pascoli The Epidemiology and Natural History of MASLD: a Global Perspective	8.30 am	<b>The Ideal Model of Care Accounting for Multidisciplinarity</b> Vito di Marco, Italy	2.50 pm	State of the art Lecture Chair: Roberto Vettor, Paolo Angeli, Volkan Yumuk The new EASL-EASO guidelines on MASLD	
	Patrick Kamath, USA	8.50 am	Responding to Stigma and Discrimination of Patients with MASLD		Phil Newsome, UK	
3.30 pm	<b>Third Session:</b> Burden and Natural History of Advanced Chronic Liver Disease Chairs: Umberto Cillo; Giacomo Germani		<ul> <li>The Role of Patients and Their Associations Marko Korenjak, Belgium</li> <li>The Role of EASL Francesco Paolo Russo, Italy</li> </ul>	3.20 pm	Seventh Session: Prevention of Progression to Advanced Chronic Liver Disease and its Complications	
3.30 pm	<b>The Burden of Advanced Chronic Liver Disease</b> Paolo Angeli, Italy		- <b>The Role of AISF</b> Vincenza Calvaruso, Italy	3.20 pm	Chairs: Patrizia Pontisso; Antonietta Romano News in the Management in Alcohol Related Liver Diseas	
3.50 pm	<b>The New Vision of Decompensation</b> Marta Tonon, Italy		- The Role of EASO and SIO Luca Busetto, Italy	3.40 pm	Mark Thursz, UK News in the Management of Viral Hepatitis	
4.10 pm	<b>ACLF</b> Richard Moreau, France	10.05 am	The Veneto Clinical Network for Liver Disease: The First Official Presentation	4.00 pm	Liliana Chemello, Italy News in the Management of Cholestatic	
4.30 pm	The History of Hepatic Encephalopathy		Giuseppe Dal Ben; Paolo Angeli, Italy	4.00 pm	<b>Liver Diseases</b> Ana Lleo de Nalda, Italy	
4.50 pm	Sara Montagnese, Italy Discussion: Cormina C. Combine: Chiera Mangini	10.25 am	An Update on the Veneto Region Obesity Network Giuseppe Dal Ben; Roberto Vettor, Italy	4.20 pm	Systemic Therapy in Patients with HCC	
4.50 pm	Discussion: Carmine G. Gambino; Chiara Mangini	10.45 am	Coffee break	4.20 pm	Andrea Casadei Gardini, Italy	
5.10 pm	State of the Art Lecture Chair: Pere Gines, Spain The Change of Paradigm in Hepatology: from Care to Prevention	11.00 am	State of the art lecture Chair: Paola Fioretto	4.40 pm	<b>Bacterial Infections with MDR and XDR</b> Salvatore Piano, Italy	
	Patrizia Burra, Italy		The Exposome Hypothesis in the Development of Obesity	5.00 pm	Discussion: Roberta Gagliardi; Simone Incicco	
5.40 pm	Fourth Session: LIVER SCREN Symposium		<b>and MASLD</b> Gema Fruhbeck Martínez, Spain	5.20 pm	<b>State of the art lecture</b> Chairs: Andrea Martini; Luisa Cavalletto	
	Screening of Liver Fibrosis Chairs: Massimo Bolognesi; Giancarlo Bombonato				The Thin Border between Pathophysiological	
5.40 pm	<b>The Impact of Innovative Technology</b> Laurent Castera, France		Management of Metabolic Dysfunctions in Patients with Liver Diseases: the Present and the Future Chairs: Angelo Avogaro; David Sacerdoti		Therapy and Palliative Care in Patients with Advanced Liver Disease Paolo Caraceni, Italy Meeting Wrap-Up: Outcomes and Future Perspectives Paolo Angeli; Roberto Vettor	
6.00 pm	Screening of Liver Disease: is it Cost Effective? Miquel Serra Burriel, Swiss	11.30 am	Optimization of the Treatment of Diabetes in Patients with Liver Disease	Meetina W		
6.20 pm	<b>Best Screening Strategies in the General Population</b> Maja Sofie Thiele, Denmark		Elisabetta Bugianesi, Italy			
6.40 pm	The Liver-Screen Project Pere Gines, Spain	11.50 am	Optimization of the Treatment of Obesity in Patients with Liver Disease Luca Busetto, Italy			
7.00 pm	Discussion: Pietro Guerra; Nicola Zeni					